Northern Trust Corp grew its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 24.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 391,990 shares of the biotechnology company’s stock after purchasing an additional 77,744 shares during the period. Northern Trust Corp owned approximately 0.78% of Aimmune Therapeutics worth $8,059,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in shares of Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,634 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Aimmune Therapeutics in the 2nd quarter valued at about $333,000. American International Group Inc. lifted its stake in shares of Aimmune Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 1,070 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Aimmune Therapeutics in the 2nd quarter valued at about $442,000. 72.84% of the stock is currently owned by institutional investors and hedge funds.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 47,425 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the sale, the insider now directly owns 34,300 shares in the company, valued at approximately $1,181,292. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Susan E. Barrowcliffe sold 18,390 shares of Aimmune Therapeutics stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.00, for a total value of $404,580.00. Following the sale, the insider now owns 3,223 shares in the company, valued at $70,906. The disclosure for this sale can be found here. Insiders have sold a total of 315,815 shares of company stock worth $8,337,379 over the last three months. 24.56% of the stock is currently owned by corporate insiders.

Several equities analysts recently commented on AIMT shares. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 27th. Zacks Investment Research raised Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research report on Wednesday. Wedbush reissued an “ourperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, August 14th. Credit Suisse Group boosted their price target on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $46.75.

Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at $33.77 on Friday. Aimmune Therapeutics, Inc. has a 52-week low of $15.97 and a 52-week high of $37.50.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.09. research analysts anticipate that Aimmune Therapeutics, Inc. will post -2.48 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-shares-bought-by-northern-trust-corp/1694993.html.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.